期刊
CANCER RESEARCH
卷 70, 期 8, 页码 3042-3051出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-3761
关键词
-
类别
资金
- NIH [CA83133, CA126820, AR27214, CA118182, CA119335-03]
- Department of Defense [W81XWH-06-1-052]
- California Breast Cancer Research Program
- NIH Kirschstein-NRSA
- Pancreatic Action Network-AACR
- California Tobacco Related Disease Research Program
Recent studies have shown that lymphangiogenesis or the growth of lymphatic vessels at the periphery of tumors promotes tumor metastasis to lymph nodes. We show here that the fibronectin-binding integrin alpha 4 beta 1 and its ligand fibronectin are novel functional markers of proliferative lymphatic endothelium. Tumors and lymphangiogenic growth factors, such as vascular endothelial growth factor-C (VEGF-C) and VEGF-A, induce lymphatic vessel expression of integrin alpha 4 beta 1. Integrin alpha 4 beta 1 then promotes growth factor and tumor-induced lymphangiogenesis, as genetic loss of integrin alpha 4 beta 1 expression in Tie2Cre+ alpha 4(loxp/loxp) mice or genetic loss of alpha 4 signaling in alpha 4Y991A knock-in mice blocks growth factor and tumor-induced lymphangiogenesis, as well as tumor metastasis to lymph nodes. In addition, antagonists of integrin alpha 4 beta 1 suppress lymphangiogenesis and tumor metastasis. Our studies show that integrin alpha 4 beta 1 and the signals it transduces regulate the adhesion, migration, invasion, and survival of proliferating lymphatic endothelial cells. As suppression of alpha 4 beta 1 expression, signal transduction, or function in tumor lymphatic endothelium not only inhibits tumor lymphangiogenesis but also prevents metastatic disease, these results show that integrin alpha 4 beta 1-mediated tumor lymphangiogenesis promotes metastasis and is a useful target for the suppression of metastatic disease. Cancer Res; 70(8); 3042-51. (C) 2010 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据